SUNDAY |
2:00 pm - 9:00 pm |
Arrival and Check-in (Office Closed 6:00 pm - 7:00 pm) |
6:00 pm |
Dinner |
7:30 pm - 7:45 pm |
Welcome / Introductory Comments by GRC Site Staff and Chairs |
7:45 pm - 9:30 pm |
Metals in Disease - New Frontiers in Iron Homeostasis |
|
The Metals in Medicine GRC covers a broad range of topics that have evolved to provide an alternative to the traditional carbon-based approach to drugs. The successes include Pt-based drugs as well as agents that are used as MRI imaging and radiopharmaceutical agents. Metals ions as vitamins are essential nutrients. They serve as key components in proteins, and countless places in metabolism. Indeed, iron homeostasis central to human well being, is maintained by many newly identified genes and impacts diseases afflicting millions of Americans with, e.g. hemochromatosis, Sickle Cell disease, Thalassemia, iron deficiency anemia and several disease of the central nervous system; iron levels are closely monitored by physicians. A recent example of the US FDA approval of the ultrasmall iron oxide nanoparticle ferumoxytol to treat iron deficiency in patients with chronic kidney disease. In this introductory session of the Metals in Medicine conference three presentations on processes associated with iron metabolism will be presented. First, current and future targets will be overviewed and presented. Second, a mechanistic presentation will illustrate the strategy of mechanistic studies paving the way for developments of devising a strategy for a cure. Finally, the third presentation involves the use of phenomenological data in nutrition to connect metal availability and disease state highlighting the many infections that eventually occur in this compromised human patient population. |
|
Discussion Leaders: Debbie C. Crans (Colorado State) and Jan Reedijk (Leiden University) |
7:45 pm - 8:15 pm |
Elizabeth Theil (CHORI, UC Berkeley) "Iron in disease, a target for 21st century therapeutics" |
8:15 pm - 8:25 pm |
Discussion |
8:25 pm - 8:50 pm |
Louis Brenner (AMAG Pharmaceuticals, Inc.) "Ferumoxytol - a Iron Oxide Nanoparticle For Treatment of Iron Deficiency Anemia" |
8:50 pm - 9:00 pm |
Discussion |
9:00 pm - 9:25 pm |
Peggy Carver (University of Michigan) "Correlating plasma concentrations of iron and trace metal ions with Infection in patients undergoing long-term home total parenteral nutrition" |
9:25 pm - 9:30 pm |
Discussion |
9:45 pm - |
Chair's Reception |
MONDAY |
7:30 am - 8:30 am |
Breakfast |
8:30 am |
Group Photo |
9:00 am - 12:30 pm |
Platinum Anticancer Agents |
|
Clinical and pre-clinical studies on platinum-based antitumor agents will be presented. The chair will present new mechanistic results and developments in imaging and tracking of the intracellular fate of platinum drugs. In addition, the session chair will introduce the topic of new clinical trials, a theme to be further expanded on by invited speakers. Two industrial speakers will provide perspective on the latest clinical results of new agents and/or formulations in clinical trials as well as briefly give background on the processes of drug development including intellectual property, financing and regulatory (FDA approval) issues. Two academic speakers presentations will include description of (i) the chemistry, biology and clinical potential of a new class of drugs structurally distinct from that of the Cisplatin and (ii) the mechanistic and clinical implications of platinum drug cellular accumulation in Cisplatin-sensitive and resistant human tumor cells. |
|
Discussion Leader: Nicholas P. Farrell (Virginia Commonwealth University) |
9:00 am - 9:30 am |
Stephen B. Howell (Moores UCSD Cancer Center) "Copper transporters regulate the cellular pharmacology of the platinum drugs" |
9:30 am - 9:45 am |
Discussion |
9:45 am - 10:15 am |
Ulrich Bierbach (Wake Forrest University, NC) "Non-crosslinking platinum-acridine agents: a new strategy for tackling chemoresistant cancers" |
10:15 am - 10:30 am |
Discussion |
10:30 am - 11:00 am |
Coffee Break |
11:00 am - 11:30 am |
Stephen J. Currier (Poniard Pharmaceuticals) "Picoplatin Injection: Getting to Market - Treating Small Cell Lung Cancer" |
11:30 am - 11:45 am |
Discussion |
11:45 am - 12:15 pm |
TBA (industrial expert on formulation of Pt-drugs) |
12:15 pm - 12:30 pm |
Discussion |
12:30 pm |
Lunch |
1:30 pm - 4:00 pm |
Free Time |
4:00 pm - 6:00 pm |
Poster Session |
6:00 pm |
Dinner |
7:30 pm - 9:30 pm |
Nuclear Medicine, Radioimmunotheraphy and Applications |
|
A session including aspects of nuclear medicine, radioimmunotheraphy and applications of some well-known and novel clinically used agents, including Technetium-99, and Fluorine-18 under development. Industrial participation and approaches in academia for translational research to document recent developments on its way and in the clinics. |
|
Discussion Leader: Alan Packard (Children’s Hospital, Harvard Medical School) |
7:30 pm - 7:45 pm |
Alan Packard (Children’s Hospital, Harvard Medical School) "Introducing current advances and challenges in nuclear medicine and readioimmunotheraphy" |
7:45 pm - 8:15 pm |
John F. Valliant (McMaster University) "State-of-the-art Tc-99m chemistry" |
8:15 pm - 8:20 pm |
Discussion |
8:20 pm - 8:50 pm |
Michael Welch (Washington University in St. Louis) "Metal Based agents for PET, from Concept to the Clinic" |
8:50 pm - 8:55 pm |
Discussion |
8:55 pm - 9:25 pm |
Simon Robinson (Lantheus) "Discovery and development of a 18F pyridazinone analog, BMS747158, for myocardial perfusion PET imaging" |
9:25 pm - 9:30 pm |
Discussion |
TUESDAY |
7:30 am - 8:30 am |
Breakfast |
9:00 am - 12:30 pm |
Responsive Magnetic Resonance Imaging (MRI) Contrast Agents |
|
This session introduced by Professor Angelique Louie covers the development of new metal ion based MRI contrast agents reporting on their environment through specific molecular recognition events. Such responsive agents would register changes in pH, temperature and even metabolite concentration and are presented by Eva Toth and by Janet Morrow. The development of MRI contrast agents that localize to a specific cell tissue type and may bind specifically to cell receptors or compounds on cell surfaces will be discussed by Silvio Aime and Martin Breichbiel. |
|
Discussion Leader: Angelique Louie (University of California, Davis) |
9:00 am - 9:30 am |
Eva Toth (Centre de Biophysique Moleculaire, CNRS, Orleans, France) "Enzymatically activated PARACEST agents" |
9:30 am - 9:45 am |
Discussion |
9:45 am - 10:15 am |
Martin Breichbiel (NIH) "On the road to development of actively targeted dendrimer-based MR contrast agents" |
10:15 am - 10:30 am |
Discussion |
10:30 am - 11:00 am |
Coffee Break |
11:00 am - 11:30 am |
Silvio Aime (I.F.M., Italy) "Metal containing nanosized system of MR imaging" |
11:30 am - 11:45 am |
Discussion |
11:45 am - 12:15 pm |
Janet Morrow (SUNY, Buffalo) "Lanthanide complexes as responsive agents for optical and MR imaging" |
12:15 pm - 12:30 pm |
Discussion |
12:30 pm |
Lunch |
1:30 pm - 4:00 pm |
Free Time |
4:00 pm - 6:00 pm |
Poster Session |
6:00 pm |
Dinner |
7:30 pm - 9:30 pm |
New breaking topics I: Alzheimers, Neurodegenerative, Heart and Stroke Illnesses, Cellular Processes and Nanoscience |
|
Topics to be selected by the end of 2009, based on recent breakthroughs selected from areas in Alzheimers and neurodegenerative illnesses, Cu- and cellular processes, heart and stroke, and nanoscience. Industrial participation is paramount. |
|
Discussion Leader: TBA |
7:30 pm - 8:00 pm |
TBA |
8:00 pm - 8:10 pm |
Discussion |
8:10 pm - 8:40 pm |
Bernard Meunier (Palumed) "Redox active metal ions in trioxane-containing antimalarial drugs" |
8:40 pm - 8:50 pm |
Discussion |
8:50 pm - 9:20 pm |
TBA |
9:20 pm - 9:30 pm |
Discussion |
WEDNESDAY |
7:30 am - 8:30 am |
Breakfast |
9:00 am - 12:30 pm |
New Investigator, Student, Postdoctoral and Industrial Session |
|
Presentations will be selected from abstracts submitted by attendees to the 2010 Gordon Conference by the chairs and presiders. This session will allow us to showcase the young and researchers that have not previously presented at a GRC. Potential presenters indicate at the time of submission of their application to the GRC for acceptance to the Gordon Conference whether they are interested in contributing to this session. There will be three categories for these presentations, a session for students and postdoctoral fellows, a session for new investigators (defined as having attended less than 5 Gordon Conferences in the past) and Industrial Contributors. To be eligible to be considered for this conference the potential presenter must either be a student, a post doctoral fellow, a young investigator or having attended less than five Gordon Conferences in the past. |
|
Discussion Leaders: Ken Raymond (UC Berkeley), Stephen Lippard (MIT), TBA (industrial participant) |
9:00 am - 10:00 am |
Student and Postdoctoral Session |
|
Discussion Leader: Kenneth N. Raymond (UC Berkeley) |
9:00 am - 9:10 am |
TBA |
9:10 am - 9:15 am |
Discussion |
9:15 am - 9:25 am |
TBA |
9:25 am - 9:30 am |
Discussion |
9:30 am - 9:40 am |
TBA |
9:40 am - 9:45 am |
Discussion |
9:45 am - 9:55 am |
TBA |
9:55 am - 10:00 am |
Discussion |
10:00 am - 10:30 am |
Coffee Break |
10:30 am - 11:30 am |
Young or New Investigators to GRCs |
|
Discussion Leader: Stephen J. Lippard (MIT) |
10:30 am - 10:40 am |
TBA |
10:40 am - 10:45 am |
Discussion |
10:45 am - 10:55 am |
TBA |
10:55 am - 11:00 am |
Discussion |
11:00 am - 11:10 am |
TBA |
11:10 am - 11:15 am |
Discussion |
11:15 am - 11:25 am |
TBA |
11:25 am - 11:30 am |
Discussion |
11:30 am - 12:30 pm |
Industrial Contributors |
|
Discussion Leader: TBA (industrial participant) |
11:30 am - 11:40 am |
TBA |
11:40 am - 11:45 am |
Discussion |
11:45 am - 11:55 am |
TBA |
11:55 am - 12:00 pm |
Discussion |
12:00 pm - 12:10 pm |
TBA |
12:10 pm - 12:15 pm |
Discussion |
12:15 pm - 12:25 pm |
TBA |
12:25 pm - 12:30 pm |
Discussion |
12:30 pm |
Lunch |
1:30 pm - 4:00 pm |
Free Time |
4:00 pm - 6:00 pm |
Poster Session |
6:00 pm |
Dinner |
7:30 pm - 9:30 pm |
Advances in The Design of Non-Pt Anticancer Agents |
|
Clinical and pre-clinical studies on non-platinum-based antitumor agents will be presented as a follow up to the earlier session on Pt-agents. The chair will begin with an overview and new results and developments pointing to new promising drugs in the pipeline. Each of the speakers will cover different areas of non-platinum agents including, gold, and Ru. The targets, mechanism of action, pre-clinical and clinical implications will be described. |
|
Discussion Leader: Peter Sadler (University of Warwick, England) |
7:30 pm - 8:00 pm |
Sue Berners-Price (Griffith University, Brisbane Australia) "Gold-based, mitochondria-targeted anticancer compounds" |
8:00 pm - 8:10 pm |
Discussion |
8:10 pm - 8:40 pm |
Michael J. Hannon (University of Birmingham, England) |
8:40 pm - 8:50 pm |
Discussion |
8:50 pm - 9:20 pm |
Enzo Alessio (University of Trieste, Italy) |
9:20 pm - 9:30 pm |
Discussion |
THURSDAY |
7:30 am - 8:30 am |
Breakfast |
9:00 am - 12:30 pm |
New breaking topics II |
|
To be selected by the end of 2009, based on recent breakthroughs selected from areas in nanomedicines, diabetes, chelators for brain metals, anti-microbial resistance. Industrial participation is paramount. |
|
Discussion Leader: Joan Valentine (UCLA) |
9:00 am - 9:30 am |
TBA |
9:30 am - 9:45 am |
Discussion |
9:45 am - 10:15 am |
TBA |
10:15 am - 10:30 am |
Discussion |
10:30 am - 11:00 am |
Coffee Break |
11:00 am - 11:30 am |
TBA |
11:30 am - 11:45 am |
Discussion |
11:45 am - 12:15 pm |
Alvin Crumbliss (Duke University) "Hijacking Fe: The mechanism of Fe transport from outside the outer membrane, across the periplasm, to the cytosol in a pathogenic bacterium" |
12:15 pm - 12:30 pm |
Discussion |
12:30 pm |
Lunch |
1:30 pm - 4:00 pm |
Free Time |
4:00 pm - 6:00 pm |
Poster Session |
6:00 pm |
Dinner |
7:30 pm - 9:30 pm |
Disease Targeting and Detection |
|
Drug efficacy is improved significantly upon targeting, but with the complexities associated with metabolism remain a goal that researchers have been combating for significant time. In this section some of the recent successes will be presented. First, new approaches to electronically detecting proteins will be presented. Second, the in vivo imaging and therapeutic efficacy of a tumor-targeted corrole directed at the human epidermal growth factor receptor will be described. |
|
Discussion Leader: A. Dean Sherry (University of Texas, Dallas) |
7:30 pm - 7:45 pm |
TBA (Poster presenter selected from participant posters on-site) |
7:45 pm - 7:50 pm |
Discussion |
7:50 pm - 8:30 pm |
Thomas Meade (Northwestern) "Electronically detecting proteins" |
8:30 pm - 8:40 pm |
Discussion |
8:40 pm - 9:20 pm |
Harry Gray (Caltech) "Metallocorroles in Medicine" |
9:20 pm - 9:30 pm |
Discussion |
FRIDAY |
7:30 am - 8:30 am |
Breakfast |
9:00 am |
Depart |